In this study, FIT enriched sensitivity for colorectal cancer for all common referral symptoms, including rectal bleeding, previously excluded from FIT studies and NICE guidelines in lower-risk symptomatic patients12,24, with no colorectal cancers when both FIT values were below 10 μg Hb per g. The gene discussed is GSTM1; the disease is colorectal cancer.